<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02557594</url>
  </required_header>
  <id_info>
    <org_study_id>DA2802_BE_I</org_study_id>
    <nct_id>NCT02557594</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Assess the Safety and Pharmacokinetics of DA-2802 319mg and Viread 300mg in Healthy Male Volunteers</brief_title>
  <official_title>A Randomized, Open-label, Two-way Crossover Study to Assess the Safety and Pharmacokinetics of DA-2802 319mg and Viread 300mg After a Single Oral Dose in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase I clinical study is to evaluate the safety and pharmacokinetics of DA-2802 319mg
      and Viread 300mg after a single oral dose in healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 6, 2015</start_date>
  <completion_date type="Actual">March 8, 2016</completion_date>
  <primary_completion_date type="Actual">November 17, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under Curve(AUC)last of Tenofovir</measure>
    <time_frame>0h(before admisitration), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72h post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum of concentration(Cmax) of Tenofovir</measure>
    <time_frame>0h(before admisitration), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72h post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of maximum concentration(Tmax) of Tenofovir</measure>
    <time_frame>0h(before admisitration), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life(t1/2) of Tenofovir</measure>
    <time_frame>0h(before admisitration), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance(CL/F) of Tenofovir</measure>
    <time_frame>0h(before admisitration), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve(AUC)inf of Tenofovir</measure>
    <time_frame>0h(before admisitration), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72h post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Viread → DA-2802</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Viread 300mg(Tenofovir disoproxil fumarate)
DA-2802 319mg(Tenofovir disoproxil orotate)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DA-2802 → Viread</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Viread 300mg(Tenofovir disoproxil fumarate)
DA-2802 319mg(Tenofovir disoproxil orotate)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Viread 300mg</intervention_name>
    <description>single dose administration after 10hr fasting</description>
    <arm_group_label>Viread → DA-2802</arm_group_label>
    <arm_group_label>DA-2802 → Viread</arm_group_label>
    <other_name>Tenofovir disoproxil fumarate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-2802 319mg</intervention_name>
    <description>single dose administration after 10hr fasting</description>
    <arm_group_label>Viread → DA-2802</arm_group_label>
    <arm_group_label>DA-2802 → Viread</arm_group_label>
    <other_name>Tenofovir disoproxil orotate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 20 to 50, healthy male subjects(at screening)

          -  Body weight over 55kg, BMI between 18.0 - 27.0

          -  Volunteer who totally understands the progress of this clinical trials, make decision
             by his free will, and signed a consent form to follow the progress.

        Exclusion Criteria:

          -  Volunteer who has past or present history of any diseases following below.(liver
             including hepatitis virus carrier, kidney, neurology, immunology, pulmonary,
             endocrine, hematooncology, urinary, skeletomuscular, cardiovascular, mental disorder)

          -  Volunteer who had GI tract disease(Crohn's disease, ulcer, acute or chronic
             pancreatitis) or surgery(appendectomy, hernioplasty are excluded)

          -  Genetic disorders such as glucose-galactose malabsorption, Lapp lactose deficiency,
             galactose intolerance which is contraindication to Viread

          -  Volunteer who had hypersensitivity reaction to medicines including Tenofovir, Aspirin,
             or antibiotics

          -  exceed 1.5 times the normal range of AST, ALT at screening test before randomization

          -  history of drug abuse, or a positive urine drug screen

          -  having ETC drug or herbal medicines within 2 weeks before first administration or OTC
             drug or vitamin preparations within a week before first administration

          -  Participation in any other clinical trial involving investigational drugs within 3
             months

          -  Volunteer who had whole blood donation in 2 months, or component blood donation or
             transfusion in 1 months

          -  Regular alcohol consumption(over 21 units/week, 1unit=10g of pure alcohol) or
             volunteers who cannot abstain from drinking during the study

          -  Volunteers smoking over 10 cigarettes per day or who cannot abstain from smoking
             during the study(from 24hr before admission to discharge)

          -  Volunteers who had grapefruit containing foods from 24hr before admission to discharge
             or who cannot abstain from grapefruit containing foods

          -  Volunteers who are not using adequate contraception methods or have a pregnancy plan

          -  volunteers who cannot abstain from caffeine containing foods(coffee, tea, soft drinks
             etc) during the study

          -  any condition that, in the view of the investigator, would interfere with study
             participation
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-sang Yu, Ph.D, M.B.A</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trial Center, Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2015</study_first_submitted>
  <study_first_submitted_qc>September 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2015</study_first_posted>
  <last_update_submitted>April 10, 2017</last_update_submitted>
  <last_update_submitted_qc>April 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis B</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

